For brand and insights teams

Evidence for the decisions in your brand plan.

Starling turns public conversation and AI answers into monthly or quarterly reports, each one tied to a question your team agreed up front.

Talk to us See a sample report

Sound familiar?

Five questions brand teams bring to us, and what answers each one.

Question 1

What are patients saying that our research didn't ask?

Twelve months of public patient conversation, read against your questions and then tracked, in patients' own words and separated from clinicians and brand accounts.

Landscape study · Answer reports

Question 2

What does ChatGPT tell patients about our brand?

Which brands ChatGPT, Gemini and Google's AI name when patients ask about their condition, and which sources they cite, tracked monthly.

Share of voice in AI answers

Question 3

What changed after the congress?

A short read soon after the event: what was said, by whom, and how patients reacted.

Event briefs

Question 4

How do we compare with our competitors?

Your brand against the agreed competitors, in social media and AI answers, measured against the baseline.

Share of voice, social and AI

Question 5

Is it safe to use?

Adverse events screened continuously and forwarded to your pharmacovigilance protocol, with no private individual ever named.

Built into every programme

How it runs

Step 1

Scope

Start from the questions in your brand plan, with the safety protocol agreed up front so nothing surprises your pharmacovigilance team.

Step 2

Landscape

A full baseline of what patients, clinicians and competitors said over the past twelve months, to measure every later change against.

Step 3

Calibrate

A working session to drop the questions that don't help and sharpen the ones that do, so every report earns its place.

Ongoing

Track

Monthly or quarterly updates to stay on top of your audiences and competitors, with adverse events screened throughout.

Three ways to work with us

A study, a subscription, or both.

Study only

Fixed fee

Best when you need a baseline or a one-time answer before a launch or congress.

Subscription only

Annual, priced by rhythm: quarterly or monthly

Best when you want tracking from now on; we build a lighter baseline in the first month.

Study + subscription

Fixed fee, then annual

Best when you want the full picture first, then every month measured against it.

Subscriptions include the platform licence, adverse-event handling and language reading.

Add Japan to any programme

Most programmes cover the US and Europe. When your brand has a Japanese market, a Japanese partner or an Asia-Pacific launch ahead, we add the Japanese patient and competitor conversation, read in Japanese by people who know the market.

How we safeguard patients and keep you compliant

Patients stay protected

We read public conversation only. Closed groups, gated patient networks and login-only forums stay private.
No private individual is ever named in a report. We cite organisations and public figures, and lightly paraphrase patient posts.
When a question needs patient interviews, we hand it to a primary-research partner, ours or yours, with a brief built from the listening.

You stay compliant

Trained readers screen for adverse events continuously and forward them under your pharmacovigilance protocol on business days.
Source links sit in an internal appendix under the agreed protocol, so the circulated report stays clean.
Patients and clinicians are separated by classification.

You know what to expect

Senior people read and interpret every report themselves, with automation doing the heavy lifting. The people you brief are the people who do the analysis, from scoping to the last report.

Get in touch

Starling GmbH
Zurich, Switzerland

The person who reads this is the person who runs the work. Expect a reply from one of us, not a form letter.

Kevin on LinkedIn Nina on LinkedIn